Critical pathway for acute ST-segment elevation myocardial infarction: estimating its potential impact in the TIMI 9 Registry.
BACKGROUND
Physicians are under increasing pressure to reduce costs and maintain high quality of care. Critical pathways may help accomplish this goal.


METHODS
We assessed the potential impact of implementation of a critical pathway in the Thrombolysis in Myocardial Infarction (TIMI 9) Registry, in which 840 consecutive patients with ST-elevation myocardial infarction (STEMI) were enrolled at 20 hospitals in the United States and Canada. The proposed critical pathway targets 100% use of fibrinolysis in fibrinolytic-eligible patients, 95% use of aspirin, and 90% use of beta-blockers and angiotensin-converting enzyme inhibitors (ACE-I) and incorporates a strategy of early hospital discharge for low-risk patients. Risk reduction for each intervention was estimated based on the benefits seen in large randomized controlled clinical trials or meta-analysis.


RESULTS
In the TIMI 9 Registry, fibrinolysis was used in 60% of the patients; primary percutaneous coronary intervention, in 9%; and no reperfusion therapy, in 31%. Only 87% of the registry patients took aspirin during hospitalization. Of those with documented left ventricular dysfunction or congestive heart failure, 32% were discharged on ACE-I; and of those with normal ejection fraction and no evidence of congestive heat failure, only 58% were treated with beta-blockers at discharge. For early benefit and by increasing the use of reperfusion therapy and aspirin to 95% and improving the time to treatment, one could potentially save 13 lives per 1,000 patients treated per year. Similarly, if beta-blocker and ACE-I use increased up to 90% for the long term, almost 2 lives per 1,000 patients treated per year could potentially be saved. In summary, by expanding the use of a critical pathway for thrombolysis in STEMI, 15 lives per 1,000 patients treated per year could be saved. To evaluate the potential economic impact of this critical pathway on low-risk patients, 358 of 505 thrombolysis patients had no recurrent ischemia, MI, shock, or congestive heart failure through day 5. Their median length of stay was 6.7 days (25-75th percentiles, range, 4.8-10.3 days), with 73% staying in-hospital more than the target of 5 days, with similar findings for patients treated with primary angioplasty.


CONCLUSIONS
These findings demonstrate that significant opportunities exist for improving medical management of patients with acute MI. Critical pathways may help reduce costs while improving quality of care.
Bahit
Maria Cecilia
MC
TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Murphy
Sabina A
SA
Gibson
C Michael
CM
Cannon
Christopher P
CP